<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832946</url>
  </required_header>
  <id_info>
    <org_study_id>GALACTIC-1</org_study_id>
    <secondary_id>2018-002664-73</secondary_id>
    <nct_id>NCT03832946</nct_id>
  </id_info>
  <brief_title>A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galecto Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galecto Biotech AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF
      (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the efficacy and safety of TD139, a galectin-3 inhibitor,
      administered by dry powder inhalation over 52 weeks. Subjects will continue on their existing
      standard of care (SoC), including pirfenidone or nintedanib. Two doses of TD139, each given
      once per day, will be compared to placebo. A follow up period of up to 52 weeks, where the
      subjects remain on their designated treatment, will provide valuable information on the
      longer-term safety of TD139 in IPF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects eligible for the study will be randomised into one of the three treatment arms:
A. TD139 10 mg once a day B. TD139 3 mg once a day C. TD139 Placebo once a day</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study is a double-blind study. The blinding will be maintained throughout the study, including the follow up period.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Annual rate of decline in Forced Vital Capacity (FVC)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Efficacy of TD139 as measured by the annual rate of decline in FVC expressed in mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute decline in FVC &gt;10%</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of subjects with an absolute decline from baseline in FVC (% predicted) of &gt; 10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to first hospitalization related to Idiopathic Pulmonary Fibrosis (IPF), including acute exacerbation of IPF expressed in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to death from all-causes, respiratory-related causes and/or caused by IPF expressed in days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Absolute decline in FVC &gt;5%</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of subjects with an absolute decline from baseline in FVC (% predicted) of &gt; 5%</description>
  </other_outcome>
  <other_outcome>
    <measure>6-minute walk test (6MWT) distance</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in distance walked (metres) over 6 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Diffusion capacity of the lung for carbon monoxide (DLCO)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in DLCO, corrected for Hemaglobin (mmol/min/kPa)</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Dyspnea using the University of California San Diego - Shortness of Breath Questionnaire (UCSD - SOBQ)</measure>
    <time_frame>Weeks 12, 26 and 52</time_frame>
    <description>Change from baseline in UCSD - SOBQ Scored from 0-120 where a higher score indicates worse dyspnea</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Health Related Quality of Life (HRQoL) using the Short-Form 36-Item Health Survey (SF-36)</measure>
    <time_frame>Weeks 12, 26 and 52</time_frame>
    <description>The Medical Outcomes SF-36 It is a self-administered questionnaire of 36-items measuring eight dimensions of general HRQoL: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). In addition to scores for individual dimensions, two summary scores assessing physical and mental dimensions of health and well-being can also be calculated: Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score, respectively. A higher score indicates a more favourable state of health</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Respiratory Related Quality of Life using the St. George`s Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Weeks 12, 26 and 52</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a 50-item questionnaire split into three domains: symptoms, activity and impact. Weighting of both individual domains and the total score produces a range from 0 to 100, with higher scores indicating a poorer health-related quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Adverse Events (AE) or Serious Adverse Events (SAE)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of subjects with Adverse Events (AE) or Serious Adverse Events (SAE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to hospitalization</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time in days to first hospitalization - both from respiratory causes and all causes</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to initiation of pirfenidone or nintedanib treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time in days to initiation of pirfenidone or nintedanib treatment in subjects not treated with pirfenidone or nintedanib at time of enrolment</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to termination of pirfenidone or nintedanib treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time in days to termination of pirfenidone or nintedanib treatment for subjects treated with pirfenidone or nintedanib at time of enrolment</description>
  </other_outcome>
  <other_outcome>
    <measure>Annual rate of decline in FVC in subjects never treated with pirfenidone or nintedanib</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in FVC expressed in mL for subjects who have never been treated with pirfenidone or nintedanib</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>A. TD139 10 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of TD139</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. TD139 3 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of TD139</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. TD139 Placebo once a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of TD139 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD139</intervention_name>
    <description>TD139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.</description>
    <arm_group_label>A. TD139 10 mg once a day</arm_group_label>
    <arm_group_label>B. TD139 3 mg once a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered as inhalation once a day</description>
    <arm_group_label>C. TD139 Placebo once a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects aged ≥ 40 years of age with a diagnosis of IPF established
             during the previous three years according to ATS/ERS/Fleischner criteria.

          2. Lung function parameters as follows:

               1. Forced Vital Capacity (FVC) &gt; 45% of the predicted value at screening

               2. Diffusion lung capacity for carbon monoxide (DLCO) (corrected for Hb) of 30% to
                  79% of the predicted value at screening

          3. Any existing Standard of Care (SoC) treatment (e.g. pirfenidone or nintedanib) must be
             deemed as stable before randomization

          4. Subjects must sign and date a written, informed consent form and any required
             authorization prior to initiation of any study procedures.

        Exclusion Criteria:

          1. Currently has significant airways obstruction: Forced Expiratory Volume in 1 s
             (FEV1)/Forced Vital Capacity (FVC) ratio of &lt; 0.7 at screening.

          2. Has clinical evidence of active infection, including, but not limited to, bronchitis,
             pneumonia, sinusitis, urinary tract infection, and cellulitis.

          3. Has a history of malignancy within the last 2 years with the exception of basal cell
             carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer
             requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or
             managed by observation.

          4. Has any condition other than IPF that, in the opinion of the investigator, is likely
             to result in the death of the subject within the next 2 years.

          5. Presence of other disease that may interfere with testing procedures or in the
             judgement of the Investigator may interfere with trial participation or may put the
             patient at risk when participating in this trial

          6. Is likely to receive lung transplantation within the next 12 months.

          7. Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil,
             azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary
             hypertension (e.g., bosentan), and or investigational therapy for idiopathic pulmonary
             fibrosis (IPF) or administration of such therapeutics within 4 weeks of initial
             screening (or 5 half-lives, whichever is longer). A current dose of less than or equal
             to 15 mg/day of prednisone or its equivalent is acceptable if the dose is anticipated
             to remain stable during the study.

          8. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than
             IPF) within the previous six months, including, but not limited to, the following:

               1. Unstable angina pectoris or myocardial infarction, or percutaneous coronary
                  intervention within the last 6 months

               2. Congestive heart failure requiring hospitalization

               3. Uncontrolled clinically significant arrhythmias

          9. If female, the subject is pregnant or lactating or intending to become pregnant before
             participating in this study during the study and within (5 half- lives plus 30 days)
             after last dose of the study drug; or intending to donate ova during such time period.

         10. Woman considered to be of childbearing potential who do not use highly effective birth
             control methods during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toby Maher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer, MB, ChB</last_name>
    <phone>+442037418183</phone>
    <email>Clinicaltrials@galecto.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SEC Clinical Research</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420-5310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Garver, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research Inc</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262-4871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Tannous, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paradigm Research</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001-0172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Lupercio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University Scholl of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Antin-Ozerkis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harmony Medical Research Institute, Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research for Health Improvement</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisette Delgado Sanchez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Broward Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Echarte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research Center</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bercz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Pulmonary Critical Care PLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Abel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srihari Veeraraghaven, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DC Research Works</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060-7297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binu George, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LaPorte County Institute for Clinical Research</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360-9330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ikeadi Ndukwu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hamblin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Suliman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Britt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School -Brigham and Womens Hospital (BWH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Rosas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Ettinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Enelow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonlx LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murali Ramaswamy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45276</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishant Gupta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aman Pande, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Roman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Lancaster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namita Sood, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Scieces Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Scholand, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Louvain-la-Neuve</city>
        <state>Wallon Region</state>
        <zip>1348</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonie Froidure, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An-Sofie Verstraeten, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CUB Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Bondue, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven- Campus Gasthuisberg</name>
      <address>
        <city>Leuvan</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wim Wuyts, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur site Godinne</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Dahlqvist, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Anees Medicine Professional Corporation</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Anees, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Dhar Medical Practice</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Dhar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hosp Research Inst</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Shapera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Hopitaux Universitaires Paris-Seine-Saint-Denis-Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilario Nunes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidwine Wemeau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Europen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Israel-Biet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Crestani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Jouneau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasborg Service de Pneumologie Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Kessler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Rgional et Universitaire - Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Marchand Adam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIMS Studienzentrum Bamberg GmbH</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Kirschner, Joachim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Donaustauf</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pfeifer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Grossadern der Ludwig-Maximilians-Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaus Kneidinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neville Berkman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kefar Sava</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shitrit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Institute Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mordechai Kramer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Segel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gershon Fink, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University-Hospital Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Vancheri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Blasi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Clinica Malattie dell Apparato Respiratorio</name>
      <address>
        <city>MIlan</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Harani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Mondena-AOU - Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephania Cerri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Dei Colli OSPEDALE MONALDI</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marialuisa Bocchino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Bargagli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza, PO Molinette</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Albera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi</name>
      <address>
        <city>Łódź</city>
        <state>Lodz</state>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Piotrowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Gruzlicy i Chorob Pluc, I Klinika Chorob Pluc</name>
      <address>
        <city>Warszawa</city>
        <state>Mazovia</state>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Lewandowska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Pulmonologii i Alergologii Szpitala Uniwersyteckiego w Krakowie</name>
      <address>
        <city>Kraków</city>
        <state>Małopolskie</state>
        <zip>30688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Sładek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Alergologii Pneumonologii</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomerania</state>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicja Sieminska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halina Batura-Gabryel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Arias-Guillen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Echave, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacobo Sellares, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Castillo Villagas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Villar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asuncion Nieto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estrella Fernandez Fabrellas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Burdem, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Molyneaux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazia Chaudhuri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Fletcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bibek Gooptu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree Unversity Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Spencer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Newcastle</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Forrest, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauri Saini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital (RHH)</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Bianchi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gareth Walters, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre - Respiratory North Bristol NHS Trust Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huzaifa Adamali, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Hirani, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TD139</keyword>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>Galectin-3 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

